As more competition makes its way into the specialty drug market, there will be opportunities for cost savings.
How can payers appropriately plan and manage benefit coverage with so many expensive specialty drugs coming down the pipeline?
As more biosimilar drugs gain approval, managed care organizations need to consider how to best utilize them for optimal savings.
As more of the healthcare industry moves to value-based contracts, it is imperative that managed care organizations can successfully measure outcomes.
With the proposed rebate rule now withdrawn, what will Congress do to help curb drug spend?
As digital health and therapeutic capabilities continue to grow, it is vital that managed care organizations keep one eye toward the future.
At AMCP Nexus 2019, experts weigh in on new and emerging specialty medications.
Biosimilars hold great cost savings promises for payers and patients alike—but only if prescribers and patients are willing to make the switch.
Good leaders don’t just rely on one managerial style—they get the best out of every team member by meeting their needs.
Cancer medication spending is unsustainable, but significant savings can be achieved just by reducing waste. Here’s how.